INVIMA Clarifies When Wearables Are Medical Devices in Colombia

Colombia's National Institute for Food and Drug Surveillance (INVIMA) has published Acta No. 06 of 10 June 2026. Section 3.3 records a technical concept from the Specialized Chamber for Medical Devices and In Vitro Diagnostic Reagents on watches, bracelets, bands, rings, and similar wearables that measure heart rate or other physiological variables. INVIMA's document archive lists the publication date as 19 August 2026.

The concept does not create a new decree or a separate wearable registration pathway. It clarifies how INVIMA applies the intended-purpose test and Rule 10 of Decree 4725 of 2005 to this product category.

Intended purpose, not the product's form, controls the boundary

The Chamber says a wearable's sanitary classification does not depend only on whether it looks like a consumer watch, bracelet, band, wristband, or ring, or whether it is available to the general public. The relevant factors are:

• the intended purpose declared by the manufacturer;
• the functions incorporated into the product;
• the physiological variables measured;
• the proposed clinical or non-clinical use;
• the information supplied to the user; and
• the expected consequence of the data generated.

A wearable is a medical device when the manufacturer declares, suggests, or permits its use for diagnosis, prevention, supervision, treatment, follow-up, compensation, or decision support relating to a disease, injury, deficiency, or clinical condition.

The Chamber's examples include products intended to measure, record, interpret, or alert on blood pressure, electrocardiogram (ECG), arrhythmias, atrial fibrillation, oxygen saturation, sleep apnea, clinically intended heart rate, diagnostically intended body temperature, glucose, cardiac output, or other physiological parameters used for clinical surveillance or detection of health changes.

When a wellness wearable remains outside medical-device scope

The same hardware can fall outside medical-device scope when the manufacturer's intended purpose is clearly limited to general wellness, physical activity, sports training, recreational tracking, or non-clinical self-care. The concept lists step and calorie counting, wellness-oriented sleep tracking, reminders, connectivity, geolocation, multimedia, and communication as examples.

That boundary has a condition: the product must not make diagnostic, therapeutic, disease-monitoring, pathology-detection, or clinical-alert claims. INVIMA also says that estimating heart rate or oxygen saturation does not by itself make a product a medical device when the manufacturer limits the function to wellness or general reference and expressly warns that it is not for diagnosis, treatment, or medical follow-up.

The practical distinction is therefore not simply “measurement versus no measurement.” It is whether the measurement is presented as clinical information that may influence a medical decision, prompt consultation, generate an alert about a potentially pathological event, or support disease follow-up.

Rule 10 separates Class IIa from Class IIb

When a wearable meets the medical-device definition, the Chamber treats it as an active diagnostic or monitoring device under Rule 10 of Article 7 of Decree 4725.

• Class IIa generally applies when the product enables direct diagnosis or monitors physiological processes, but variation in the measured parameter does not itself imply an immediate danger to the patient's life.
• Class IIb applies when the product is specifically intended to monitor vital physiological parameters whose variation may present an immediate danger to life, including relevant changes in cardiac, respiratory, or central-nervous-system function.

The Chamber identifies clinically significant arrhythmia detection, diagnostic ECG, sleep-apnea alerts, relevant respiratory monitoring, clinical blood- pressure monitoring, and alerts for critical physiological events as functions that may fall within Class IIb depending on the declared intended purpose and technical validation. The named function alone is not an automatic IIb assignment.

What manufacturers should review now

Pure Global recommends treating the concept as a claim-and-use audit for every wearable intended for Colombia:

1. Map each measurement and alert to its intended use. Record the target user, clinical or non-clinical context, information displayed, and action the user is expected to take.
2. Reconcile the complete user-facing presentation. Labeling, instructions, app copy, promotional claims, and alert language should all support the same intended regulatory position.
3. Make a wellness limitation explicit where that is the real purpose. Do not pair a wellness disclaimer with diagnostic, therapeutic, disease-monitoring, pathology-detection, or clinical-alert claims elsewhere.
4. Document the Rule 10 rationale for medical wearables. The IIa/IIb analysis should address whether the monitored parameter is vital, whether its variation can present immediate danger, and how the intended purpose and technical validation support the conclusion.
5. Use the Colombian rule as the filing basis. A class assigned in another jurisdiction does not replace the analysis under Decree 4725.

Read Acta No. 06, especially section 3.3, and the official Decree 4725 compilation. For broader market context, see Pure Global's Colombia market overview, INVIMA medical device classification guide, and INVIMA medical device regulations.